Denver Back Pain Specialists
- PRP Therapy
- Arthritis Treatment
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
- Stem Cell Therapy
Greenwood Village, CO
Stem Cell Therapy clinics in Greenwood Village
Greenwood Village supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through HealthONE's Swedish Medical Center and nearby UCHealth, and stem cell practice in the area spans Denver Tech Center, Cherry Hills Village border, and Arapahoe Road corridor. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Colorado regulates physician practice through the Colorado Medical Board. There is no state-specific stem cell disclosure law, so federal 21 CFR Part 1271 rules apply. The state has a strong regenerative orthopedic research presence around Denver and Boulder. The 4 Greenwood Village clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Colorado Medical Board licensure checks.
ThriveMD Denver Colorado
- Vitamin IV Therapy
- PRP Therapy
- Shockwave Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Arthritis Treatment
Colorado Stem Cell Center
- PRP Therapy
- Arthritis Treatment
- Peptide Therapy
- Stem Cell Therapy
Regulatory context
A note on Colorado's stem cell therapy rules.
Colorado cellular therapy clinics are governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without need for premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed for orthopedic, cosmetic, or neurologic conditions in Colorado are Section 351 biologics. The FDA expects compliance regardless of whether the cells are autologous.
-
Colorado Medical Practice Act, CRS Title 12, Article 240
Establishes physician licensure and the Colorado Medical Board's authority over scope of practice and discipline. -
Colorado Naturopathic Doctor Act, CRS Title 12, Article 250
Defines registered naturopathic doctor scope, which excludes most injectable cellular procedures. -
Colorado Pharmacy Practice Act, CRS Title 12, Article 280
Regulates compounding pharmacies, including 503A standards relevant to biologic preparation.
The FDA has issued warning letters and inspectional observations to Colorado clinics marketing unapproved stem cell and exosome therapies. The Colorado Medical Board has disciplined physicians for unprofessional conduct related to misleading advertising and substandard care in regenerative procedures. Colorado has not produced a high-profile injunction comparable to the California SVF case, but federal scrutiny of Front Range and resort-area clinics has been steady. The Colorado Attorney General has authority under the Colorado Consumer Protection Act to pursue deceptive trade practice claims against providers making unsupported clinical claims.